Plunkett Research Online: Adlai Nortye Ltd

ADLAI NORTYE LTD (ANL:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the cl.....



Adlai Nortye Ltd
Ticker: ANL
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 848 230-7430
Fax:
Address: 685 US Highway 1
New Jersey Biotechnology Development Center, 2nd floor
North Brunswick, NJ 08902 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
Biotechnology
Healthcare
Contacts Description
Lars BirgersonCEO, Subsidiary/Chief Medical Officer/Director/President
Yang LuCEO/Chairman of the Board/Co-Founder/Director
See More
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the cl.....See More See More

Auditor: Mazars USA LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: